Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

admin

5 months ago

By: Ibrahim Aldoss, MD – City of Hope
Date: 12/11/2023